CRNX

NEUTRALM&A

Crinetics Pharmaceuticals, Inc.

2026-08-24

Price

$84.78

+0.11%

This is the 2026-08-24 snapshot — the signals and analysis for CRNX as of this single trading day.

View full CRNX research hub →

Score9.8Priority

Signals7/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.4xvs 20d avg

Analysis

Crinetics Pharmaceuticals (CRNX) is exhibiting textbook merger arbitrage behavior, trading at $84.78 just pennies shy of Vertex Pharmaceuticals' $85 per share all-cash acquisition price. The convergence of SURGE and QUIET_STORM signals, along with an exceptionally low 2.3% realized volatility, reflects high-conviction institutional absorption as the market prices in near-absolute deal certainty. Furthermore, the broader RISK_ON liquidity regime acts as a tailwind for M&A completion, completely insulating the stock from the market's current geopolitical 'wall of worry'.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKSELLER FATIGUEWEAK FINISH

Key Takeaways

Price action is heavily anchored to the $85 Vertex acquisition price, rendering traditional technical breakouts irrelevant and capping upside [1.1.8].
Recent HSR and international antitrust clearances have de-risked the transaction, compressing the arbitrage spread to less than 0.3%.
Downside risk is strictly tied to deal failure; any breach of the $83.52 support would indicate institutional participants are pricing in unforeseen regulatory or legal hurdles.

← Back to 2026-08-24 View Full CRNX History →Yahoo Finance &nearr;